Sertraline and inflammatory markers in major depression: a systematic review and meta-analysis.

IF 3.6 3区医学 Q1 PSYCHIATRY

Annals of General Psychiatry Pub Date : 2025-09-29 DOI:10.1186/s12991-025-00596-4

ZiLiang Xie, Zheng Gao, Xue Li, Shuo Li, Fan Tang, Caiyi Zhang

{"title":"Sertraline and inflammatory markers in major depression: a systematic review and meta-analysis.","authors":"ZiLiang Xie, Zheng Gao, Xue Li, Shuo Li, Fan Tang, Caiyi Zhang","doi":"10.1186/s12991-025-00596-4","DOIUrl":null,"url":null,"abstract":"Background: Increasing evidence suggests a link between major depressive disorder (MDD) and inflammatory pathways. Sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI), may influence inflammatory cytokine levels. This systematic review and meta-analysis aimed to elucidate the association between the antidepressant sertraline and inflammatory processes and to delineate the roles of key cytokines within this context.Methods: Electronic searches of the Web of Science, MEDLINE, and Embase databases (from inception to August 8, 2025) yielded 890 unique records. The included studies measured serum concentrations of inflammatory cytokines in patients with major depressive disorder (MDD) before and after sertraline treatment, with subsequent analysis of the effects of sertraline on these biomarkers. Two independent investigators performed the literature screening and data extraction. Pooled effect estimates were calculated using random effects meta-analysis models.Results: Eleven studies (406 participants) were included. The results demonstrated significant increases in both IL-6 levels (SMD = 0.87; 95% CI: 0.16 to 1.58; Z = 2.41; p = 0.02) and TNF-α levels (SMD = 0.76; 95% CI: 0.14 to 1.71; Z = 2.30; p = 0.02) following sertraline treatment.Conclusion: Sertraline significantly modulates IL-6/TNF-α levels, suggesting that this pathway may partly mediate its antidepressant effects.","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"24 1","pages":"53"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482824/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-025-00596-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Increasing evidence suggests a link between major depressive disorder (MDD) and inflammatory pathways. Sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI), may influence inflammatory cytokine levels. This systematic review and meta-analysis aimed to elucidate the association between the antidepressant sertraline and inflammatory processes and to delineate the roles of key cytokines within this context.

Methods: Electronic searches of the Web of Science, MEDLINE, and Embase databases (from inception to August 8, 2025) yielded 890 unique records. The included studies measured serum concentrations of inflammatory cytokines in patients with major depressive disorder (MDD) before and after sertraline treatment, with subsequent analysis of the effects of sertraline on these biomarkers. Two independent investigators performed the literature screening and data extraction. Pooled effect estimates were calculated using random effects meta-analysis models.

Results: Eleven studies (406 participants) were included. The results demonstrated significant increases in both IL-6 levels (SMD = 0.87; 95% CI: 0.16 to 1.58; Z = 2.41; p = 0.02) and TNF-α levels (SMD = 0.76; 95% CI: 0.14 to 1.71; Z = 2.30; p = 0.02) following sertraline treatment.

Conclusion: Sertraline significantly modulates IL-6/TNF-α levels, suggesting that this pathway may partly mediate its antidepressant effects.

Abstract Image

查看原文本刊更多论文

舍曲林与重度抑郁症炎症标志物：系统回顾和荟萃分析。

背景：越来越多的证据表明重度抑郁症（MDD）与炎症途径之间存在联系。舍曲林是一种常用的选择性血清素再摄取抑制剂（SSRI），可能影响炎症细胞因子水平。本系统综述和荟萃分析旨在阐明抗抑郁药舍曲林与炎症过程之间的关系，并描述关键细胞因子在此背景下的作用。方法：电子检索Web of Science、MEDLINE和Embase数据库（从成立到2025年8月8日），得到890条唯一记录。纳入的研究测量了重度抑郁症（MDD）患者在舍曲林治疗前后的血清炎症细胞因子浓度，并随后分析了舍曲林对这些生物标志物的影响。两位独立研究者进行了文献筛选和数据提取。使用随机效应荟萃分析模型计算合并效应估计。结果：纳入11项研究（406名受试者）。结果显示，在舍曲林治疗后，IL-6水平（SMD = 0.87; 95% CI: 0.16至1.58;Z = 2.41; p = 0.02）和TNF-α水平（SMD = 0.76; 95% CI: 0.14至1.71;Z = 2.30; p = 0.02）均显著升高。结论：舍曲林可显著调节IL-6/TNF-α水平，提示该途径可能部分介导其抗抑郁作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of General Psychiatry PSYCHIATRY-

CiteScore

6.60

自引率

2.70%

发文量

审稿时长

>12 weeks

期刊介绍： Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.